◀ Back to CD79A
CD22 — CD79A
Pathways - manually collected, often from reviews:
Text-mined interactions from Literome
Lajaunias et al., J Immunol 2002
(Calcium Signaling) :
Moreover, in CD22-deficient mice, anti-IgM treatment did not trigger enhanced Ca ( 2+ ) influx in CD5 ( + ) B-1 cells, unlike CD22-deficient splenic B-2 cells, suggesting a relatively limited
role of
CD22 in
BCR signaling in B-1 cells
Lee et al., J Immunol 2005
:
BCR induced
CD22 phosphorylation and Src homology 2 domain containing protein tyrosine phosphatase-1/CD22 associations were also reduced, suggesting abrogation of negative regulatory signaling
Yu et al., Biochem Biophys Res Commun 2007
:
Previous studies demonstrated that synthetic sialosides that bind to CD22 augment BCR signaling by inhibiting
CD22 mediated
BCR regulation
Zhu et al., J Biol Chem 2008
:
We demonstrate that the
CD22 mutant in which both Tyr ( 843 ) and Tyr ( 863 ) are replaced by phenylalanine ( CD22F5/6 ) recruits SHP-1 and
regulates BCR signaling upon stimulation with antigen but not anti-Ig Ab
Harvey et al., BioDrugs 2013
(Lupus Erythematosus, Systemic) :
Epratuzumab is a humanized monoclonal antibody that targets CD22 on B cells and results in modulation of B-cell function and migration, as
CD22 regulates adhesion and
inhibits B-cell receptor (BCR) signalling
Sato et al., Proc Natl Acad Sci U S A 1997
:
Ligation of CD19 and
CD22 in vivo is likely to positively and negatively
regulate BCR signaling, respectively, because CD19 crosslinking was more efficient than BCR crosslinking at inducing Vav phosphorylation